MIAMI–(BUSINESS WIRE)—- $SMMT–Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the initiation of a new global Phase III clinical trial of ivonescimab, an investigational, novel PD-1 x VEGF bispecific antibody, in non-small cell lung cancer (NSCLC). The study, HARMONi-10, will evaluate ivonescimab compared with durvalumab as consolidation therapy in patients with locally advanced, unresectable Stage III NSCLC who have not experienced disease progression following platinum-based concurrent chemo

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.